# Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.

> **NCT04882462** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 100 (estimated)

## Conditions studied

- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** Sintilimab
- **DRUG:** Chemotherapy drug

## Key facts

- **NCT ID:** NCT04882462
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-01
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-05-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04882462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04882462, "Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04882462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*